CBD Flower Rise Up Untrimmed

Autor

CBD Flower Rise Up Untrimmed

CBD flower Rise Up is a relatively new strain of CBD flower Rise Up that has all the makings of a classic: a diverse terpene profile, stocky nugs with an addicting aroma, and a very pleasant “mellowing” effect.

CBD Flower Rise Up Untrimmed
CBD Flower Rise Up Untrimmed
This is the untrimmed version of CBD flower Rise Up, available in larger quantities, and is perfect for oil extractions or any form of consumption you may require. Higher quantity, without the sacrifice to quality, what’s not to like?

CBD flower Rise Up Cannabinoid Profile

CBD .81%
CBC .06%
CBDA 15.08%
CBGA .75%
D9-THC .12%
THCA .44%
Total Measured Cannanbinoids 17.39%

CBD flower Rise Up Terpene Profile

Camphene .054%
beta-Caryophyllene .082%
beta-Farnesene .112%
Fenchol .023%
Fenchone .0199%
Guaiol .032%
alpha-Humulene .040%
Linalool .021%
beta-Myrcene .23%
trans-Nerolidol .0176%
Phytol 1 .0084%
Phytol 2 .0176%
alpha-Pinene .043%
alpha-Terpineol .0139%
Terpinolene .023%
Total Measured Terpenes .73%

CBD flower Rise Up Terpene Profile is available in 3 size variants, tested at 15.08% CBDa and contains less than 0.3% Delta 9 THC.


When I opened the bag, my first thought was “It smells like camping.” The taste is marvelous. It has some big leaves still on it, but I will just use that to make some edibles.
Only improvement would be a sticker with every order. I could be spreading 
Dr.Ganja’s message all over upstate NY with them.

Relaxing, soothing flower, great for sleep and anxiety. Great product!
Location 96 4th St, Brooklyn, NY 11231, США

Комментарии

Отправить комментарий

Популярные сообщения из этого блога

Cannabis Stocks Rally Start Fast Growth

Autor
Изображение
Cannabis News DrGanja Cannabis Stocks Rally Start Fast Growth After FDA Says It will Speed Up Create Rules For CBD  Cannabis stocks were mostly higher on Monday, after the U.S. Food and Drug Administration said it is expediting its effort to create a regulatory framework for CBD with plans to publish a report on its progress by early fall. Amy Abernathy, acting chief information officer, said in a series of tweets sent on Friday that the agency is “expediting its work to address the many questions about cannabidiol . This is an important national issue with public health impact, and an important topic for American hemp farmers and many other stakeholders.” The FDA is still working its way through the public comments posted after more than 100 speakers presented at a May 31 public hearing on the subject, she said, urging anyone who still plans to submit information to do so by Tuesday.
Read More

CBD Hemp Oil Important Information

Autor
Изображение
CBD is a natural substance derived from the cannabis plant. Since CBD oil contains both psychoactive and technical varieties of cannabis , it is only natural that there are concerns about its legality and safety. You need to know that some components of cannabis are beneficial to health and treatment, and also do not possess psychoactive properties. CBD oil is just such a pretty powerful ingredient. Currently, it is hotly debated among supporters of natural medicines, claiming its usefulness in the treatment of a wide range of diseases from chronic pain to cancer. CBD Oil Let's see what a CBD oil is, how best to use it and scientific opinion about its benefits. What is CBD oil? Cannabidiol (CBD) is one of over one hundred cannabinoids found in cannabis. Thanks to the appropriate receptors, this component spreads throughout the body and enters the brain. Extracted from a CBD plant is diluted with coconut or olive oil . It can also be obtained from hemp ,
Read More

Aphria Inc. Is First Canadian Cannabis Manufacturer to Turn a Profit

Autor
Изображение
Aphria Inc. Is First Canadian Cannabis Manufacturer to Turn a Profit Aphria Inc. Is First Canadian Cannabis Manufacturer to Turn a Profit Aphria Inc. became the first major Canadian cannabis manufacturer to report a net profit Thursday, sending its shares up 32% in post-market trading. The Leamington, Ontario-based  pot producer  said it earned C$15.8 million ($12 million) in the quarter ended May 31 on revenue of C$129 million. The revenue figure beat the highest analyst estimate, and was up 75% from the prior quarter. The results are a remarkable shift from last quarter, when Aphria  reported  a significant drop in gross margin, revenue that missed expectations and a C$50 million writedown on its Latin American assets. Key Insights Revenue from recreational  cannabis  sales was C$18.5 million, up 158% from the prior quarter, on 5,574 kilograms of cannabis soldIt also cost Aphria less to  produce pot , with cash cost per gram of dried cannabis falling to C$1.35 fro
Read More